Overview

ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)

Status:
Active, not recruiting
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)
Phase:
Phase 3
Details
Lead Sponsor:
Fudan University
Treatments:
Cisplatin
Gemcitabine